On September 5, 2023 Beactica Therapeutics AB, the Swedish precision oncology company, reported the selection of BEA-17 as a preclinical candidate for its LSD1 programme aimed at finding new therapies for aggressive brain tumours and other life-threatening cancers (Press release, Beactica, SEP 5, 2023, View Source [SID1234634920]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BEA-17 is a first-in-class small molecule which has shown promising potentiation of immune-modulating treatments in preclinical models of several cancer forms. BEA-17 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of glioblastoma (GBM), the most aggressive form of brain tumour. With the selection of this first preclinical candidate, IND-enabling toxicology studies will be initiated in preparation for clinical trials.

"We are thrilled to announce the selection of BEA-17 as a preclinical candidate. Reaching this remarkable milestone is a major achievement, as the vast majority of programmes fail at the preclinical stage." said Dr Per Källblad, CEO of Beactica Therapeutics. "The selection of this molecule reflects our aim to test this new approach in humans as quickly as possible."

About BEA-17

BEA-17 is a first-in-class small molecule targeted degrader (non-PROTAC) of lysine demethylase 1 (LSD1) and its co-factor CoREST. In syngeneic animal models of cancer, the compound has shown promising potentiation of immune-modulating treatments in several cancer forms, including anti-PD1 checkpoint inhibitors in colon cancer (CT26) and standard of care (temozolomide and radiation) in glioblastoma (GL261). Pharmacokinetic studies of BEA-17 show good blood-brain-barrier penetration and oral availability. BEA-17 is investigational and not approved anywhere globally. Its efficacy and safety in humans have not been established. BEA-17 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of glioblastoma (GBM).

On September 5, 2023 IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, reported its participation in upcoming investor relations events (Press release, Ideaya Biosciences, SEP 5, 2023, View Source [SID1234634919]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi 18th Annual BioPharma Conference
Wednesday, September 6th, 2023 at 1:00 PM ET

Targeted Oncology Panel participation by Paul Stone, Chief Financial Officer, hosted by Yigal D. Nochomovitz, Ph.D., Director, SMid Cap Biotech Analyst.
Morgan Stanley 21st Annual Global Healthcare Conference
Monday, September 11th, 2023 at 10:40 AM ET

Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Ryuk Byun, MD, Executive Director.
A live audio webcast of conference events, as permitted by conference host, will be available at the "Investors/News and Events/Investor Calendar" section of the IDEAYA website at View Source and/or through the conference host. A replay of available webcasts will be accessible for 30 days following the live event.

On September 5, 2023 I-Mab (Nasdaq: IMAB) (the "Company"), is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics for oncology, reported its participation in the following conferences in September 2023 (Press release, I-Mab Biopharma, SEP 5, 2023, View Source [SID1234634918]). Details of the conferences and management presentation are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 25th Annual Global Investment Conference (Hybrid)

Presentation: Monday, September 11th at 11:30 a.m. E.S.T

Presenter: Mr. Raj Kannan, CEO

One-on-one and small group meetings: Sept 11-13, 2023

Management participants: Mr. Raj Kannan, CEO; Dr. John Hayslip, CMO; Dr. Andrew Zhu, President and Head of R&D; and Mr. Tyler Ehler, Senior Director, Investor Relations

For more information, please contact your H.C. Wainwright representative.

2023 Cantor Global Healthcare Conference (In Person)

Presentation: Thursday, September 28th at 2:25 p.m. E.S.T.

Presenter: Mr. Raj Kannan, CEO; and Dr. John Hayslip, CMO

One-on-one and small group meetings: Sept 26-28, 2023

Management participants: Mr. Raj Kannan, CEO; Dr. John Hayslip, CMO; and Mr. Tyler Ehler, Senior Director, Investor Relations

For more information, please contact your Cantor representative.

On September 5, 2023 Acupath Labs reported a white paper highlighting the impressive results of a large-scale internal study analyzing the clinical utility of its Acu-UR017 bladder cancer biomarker (Press release, Acupath Laboratories, SEP 5, 2023, View Source [SID1234634917]). Acu-URO17 is a non-invasive, cost-effective urine-based biomarker used in the diagnosis and management of bladder cancer, the 6th most common form of cancer in the US. Commercially launched nationwide in 2019, Acupath has performed over 25,000 tests and has helped urology practices nationwide leverage the inherent and significant clinical and financial benefits of the assay.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Primary positioned as a "rule out" tool, Acu-URO17 had a negative predictive value (NPV) of 99.9%, thus helping to offset the problematic low sensitivity of traditional urine cytology, while at the same time serving as a valuable risk-stratification tool on atypical urine cytology diagnoses. Further, Acu-URO17 had a sensitivity of 96% and specificity of 82% on urine cytology cases that yielded high-grade urothelial cancer diagnoses. These results are consistent with the three peer-reviewed studies that have previously been published.

"Our team has worked tirelessly over the last 4+ years to optimize this assay and make it available to clients nationwide, and these results support the significant value that Acu-URO17 provides for both clinicians and patients. We will continue working with our clients and industry partners to increase the adoption of Acu-URO17 and provide support and guidance to urology practices and labs that seek to incorporate Acu-URO17 into their existing operations.", says John Cucci, Chief Sales Officer of Acupath.

"I have seen firsthand the clinical utility provided by Acu-URO17, especially when performed in conjunction with both traditional urine cytology and FISH. This innovative biomarker has consistently demonstrated its ability to help clinicians triage patients at risk of bladder cancer and provide the best possible diagnostic and treatment plan.", says Michael Matthews, Director of Molecular Diagnostics at Acupath.

For a PDF of the white paper and / or information on how to order Acu-URO17 or incorporate into your lab, email [email protected].

On September 5, 2023 Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, reported that the Company will participate in two upcoming investor conferences (Press release, Fusion Pharmaceuticals, SEP 5, 2023, View Source [SID1234634916]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The H.C. Wainwright 25th Annual Global Investment Conference – The Company presentation will take place on Tuesday, September 12, 2023 at 2:00 p.m. ET. Presenting on behalf of Fusion will be Chief Financial Officer John Crowley.
The Morgan Stanley 21st Annual Global Healthcare Conference – The fireside chat will take place on Wednesday, September 13, 2023 at 3:35 p.m. ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.
Webcasts of each event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 90 days following their respective presentation dates.